ACON · Aclarion Inc. Common Stock
View on chartInsiders & Stakes
| Brent Ness Chief Executive Officer | ▲ Buy | Grant | 106,300 Shares held | 6/11/2026 | View profile |
| Jeffrey John Thramann Executive Chairman | ▲ Buy | Grant | 100,000 Shares held | 6/11/2026 | View profile |
| Ryan Bond Chief Strategy Officer | ▲ Buy | Grant | 55,000 Shares held | 6/11/2026 | View profile |
| Gregory A. Gould Chief Financial Officer | ▲ Buy | Grant | 50,000 Shares held | 6/11/2026 | View profile |
| Scott Breidbart Director | ▲ Buy | Grant | 25,664 Shares held | 6/11/2026 | View profile |
| David K. Neal Director | ▲ Buy | Grant | 22,502 Shares held | 6/11/2026 | View profile |
| John Paul Lorbiecki Chief Financial Officer | ▲ Buy | Open Market | 22,404 Shares held | 12/29/2022 | View profile |
| William Wesemann Director | ▲ Buy | Grant | 21,563 Shares held | 6/11/2026 | View profile |
| Amanda Mae Sequira Director | ▲ Buy | Grant | 20,000 Shares held | 6/11/2026 | View profile |
| Stephen Deitsch Director | ▲ Buy | Grant | 20,000 Shares held | 6/11/2026 | View profile |
| SC Capital 1 LLC | ▼ Sell | Other | 0 Shares held | 12/2/2022 | View profile |
Transaction History
| William Wesemann | ▲ Buy | Grant | 20,000 | $0 | 6/11/2026 |
| Jeffrey John Thramann | ▲ Buy | Grant | 100,000 | $0 | 6/11/2026 |
| David K. Neal | ▲ Buy | Grant | 20,000 | $0 | 6/11/2026 |
| Stephen Deitsch | ▲ Buy | Grant | 20,000 | $0 | 6/11/2026 |
| Gregory A. Gould | ▲ Buy | Grant | 50,000 | $0 | 6/11/2026 |
| Brent Ness | ▲ Buy | Grant | 100,000 | $0 | 6/11/2026 |
| Ryan Bond | ▲ Buy | Grant | 55,000 | $0 | 6/11/2026 |
| Amanda Mae Sequira | ▲ Buy | Grant | 20,000 | $0 | 6/11/2026 |
| Scott Breidbart | ▲ Buy | Grant | 20,000 | $0 | 6/11/2026 |
| Scott Breidbart | ▲ Buy | Open Market | 5,664 | $18K | 5/12/2026 |
| David K. Neal | ▲ Buy | Open Market | 2,500 | $8K | 5/11/2026 |
| Brent Ness | ▲ Buy | Open Market | 6,289 | $20K | 5/11/2026 |
| William Wesemann | ▲ Buy | Open Market | 1,562 | $5K | 5/6/2026 |
| Brent Ness | ▲ Buy | Open Market | 10 | $62 | 11/26/2025 |
| Jeffrey John Thramann | ▼ Sell | Other | 1 | $1K | 3/28/2023 |
| Jeffrey John Thramann | ▲ Buy | Open Market | 1 | $1K | 2/16/2023 |
| Brent Ness | ▲ Buy | Open Market | 8,500 | $4K | 12/29/2022 |
| Brent Ness | ▲ Buy | Open Market | 7,711 | $4K | 12/29/2022 |
| John Paul Lorbiecki | ▲ Buy | Open Market | 4,100 | $2K | 12/29/2022 |
| John Paul Lorbiecki | ▲ Buy | Open Market | 18,304 | $8K | 12/29/2022 |
| Brent Ness | ▲ Buy | Open Market | 2,289 | $961 | 12/28/2022 |
| SC Capital 1 LLC | ▼ Sell | Other | 1,091,894 | $0 | 12/2/2022 |
| David K. Neal | ▼ Sell | Other | 152,128 | $0 | 12/2/2022 |
| Ryan Bond | ▲ Buy | Open Market | 20,000 | $56K | 4/22/2022 |
| William Wesemann | ▲ Buy | Open Market | 11,000 | $48K | 4/21/2022 |
| Brent Ness | ▲ Buy | Open Market | 1,000 | $4K | 4/21/2022 |
| David K. Neal | ▲ Buy | Open Market | 34,400 | $150K | 4/21/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
ACON Adds NYU Langone Health to CLARITY Trial Network
Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.
ACON Adds NYU Langone Health to CLARITY Trial Network. Aclarion Inc. announced that NYU Langone Health has joined its CLARITY Trial Network. The partnership brings the health system into 11 enrolling sites, expanding the company’s clinical trial footprint. This move could increase the pace of data collection for Aclarion’s pipeline. The announcement comes as the stock trades near its 14‑day support level.